Hartmut Ehrlich and Philippe Pouletty discuss Abivax Clinical Programs Involving Covid-19 and more.
Release Date: 12/09/2020
The Media's Viral Lie about Ivermectin Overdoses & Horse Medicine: Dr. Kory Responds | Interview
trialsitenews's podcast
In the last few weeks, the mainstream media ran with stories about Ivermectin, most noticeably referring to it as "horse medicine" or "horse dewormer" while, for some reason, leaving out the fact that Ivermectin is a WHO essential medicine for HUMANS.
info_outline
Kelly McKee from Medidata talks transforming the patient clinical trial experience
trialsitenews's podcast
An interview with Kelly McKee from Medidata on transforming the patient clinical trial experience.
info_outline
CATalyst | Indian Bar Association Serve Legal Notice on WHO's chief scientist Dr. Soumya Swaminathan
trialsitenews's podcast
info_outline
Ralph Lorigo Talks NY Court Rulings Over Ivermectin Use In Covid-19 Treatment | Interview
trialsitenews's podcast
We sit down with Ralph Lorigo, of the Law Office of Ralph C. Lorigo to discuss NY court cases regarding Ivermectin and Covid-19.
info_outline
Ralph Lorigo Talks NY Court Rulings Over Ivermectin Use In Covid-19 Treatment | Interview
trialsitenews's podcast
We sit down with Ralph Lorigo, of the Law Office of Ralph C. Lorigo to discuss NY court cases regarding Ivermectin and Covid-19.
info_outline
Shabnam Palesa Mohamed, discusses state of Ivermectin in South Africa | Podcast
trialsitenews's podcast
Shabnam Palesa Mohamed: Activist. journalist, mediator (LLB). Founder of SAHARI and THJ CEO, discusses state of Ivermectin in South Africa. We discuss the twists and turns of the legality issues of the drug, to a campaign to bring awareness through-out the country and beyond.
info_outline
Dr. Kedar discusses Covid-19 impact on bringing research to rural communities
trialsitenews's podcast
We talk with Dr. Kedar about rural research initiatives and the impact Covid-19 has had in bringing advanced research to them. Dr. Kedar specializes in autoimmune diseases that effect the musculoskeletal system, such as rheumatism, arthritis, and other disorders of the joints, muscles and ligaments.
info_outline
Melanie Rice: Patient Suffering from MS discusses her experience with the disease
trialsitenews's podcast
Melanie Rice who is suffering from Multiple Sclerosis. She was diagnosed Sept 20 2019 at the Mayo Clinic in Jacksonville Florida. Since then she has uncovered an entire community, or more appropriately, a family of thousands of people struggling with this autoimmune disease. She has become an advocate for MS patients, and so we have brought her on to talk with us about her illness.
info_outline
Sam Searcy Talks Accelerating The Clinical Trials Process With Cloud-Based Service Providers
trialsitenews's podcast
We sit down with Sam Searcy to talk about his Company Clinistart, and innovative cloud-based service providers designed to accelerate clinical trial site activation and study start up. The goal: accelerate each step of the clinical trials process to accelerate the availability of medicines sooner for patients.
info_outline
Dr. John Boockvar Of Lenox Hill Hospital Talks New Surgical Technique To Treat Glioblastoma
trialsitenews's podcast
We sit down for an interview with Dr. John Boockvar, vice chair of neurosurgery at Lenox Hill Hospital, who started a first-in-human clinical research study involving a new surgical technique to treat glioblastoma multiforme (GBM) - the most aggressive form of brain cancer.
info_outlineHartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn's Disease and more.
https://www.abivax.com/pipeline/
- #COVID-19
https://www.abivax.com/pipeline/abx464-for-covid-19/
Ongoing Phase 2b/3 trial with ABX464 in Covid-19 (miR-AGE trial), the unique properties of the lead candidate (antiviral, anti-inflammatory, tissue repair) to treat elderly and high-risk Covid-19 patients, the rial is ongoing in Europe and Brazil (Mexico, Peru and Chile to follow shortly)
-#Cancer
https://www.abivax.com/pipeline/abx196/
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies agonists of these types of cells that demonstrate immune enhancing effects in cancer models.
Preclinical data showed that ABX196 enhanced anti-tumoral activity when used alone and in combination with anti-PD1 antibodies or doxorubicin.
- Ulcerative Colitis
https://www.abivax.com/pipeline/abx464-ibd-uc/
ABX464 in Inflammatory Bowel Diseases (Abivax development priority), excellent two-year efficacy and safety data for ABX464 ulcerative colitis Phase 2a maintenance study and ongoing ulcerative colitis Phase 2b trial in 15 countries, the US and Canada
- Crohn’s disease
https://www.abivax.com/pipeline/abx464-for-crohns-disease/
Planned pivotal Phase 2b/3 trial with ABX464 in Crohn’s disease (FPI Q1 2021) and ngoing clinical trial with ABX464 in rheumatoid arthritis in 5 European countries
- HC
Ongoing clinical trial with second molecule, ABX196, in patients with hepatocellular carcinoma in the US